Full Text
Real-World Cost Per Persisting Patient- Comparing Psoriasis Patients Initiated on Apremilast or Biologic Therapies

Abstract

Authors

SR Feldman A Kuznik Z Clancy

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×